NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009

FT. MYERS, Fla., Nov. 12 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City. The conference will showcase public and private life sciences and biotech companies. Senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference. NeoGenomics is scheduled to present on Wednesday, November 18th at 9:30 AM EST in the Library Room on the second floor of the hotel. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/lz6/ngnm.ob/. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.com at the time of the conference. The webcast will be available for three months.About NeoGenomics, ...
Click here to read the whole Article (external link)

NEOGENOMICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of October 28, 2009, the Board of Directors of NeoGenomics, Inc. (the "Company") has appointed Douglas M. VanOort, age 53, to the position of Chief Executive Officer. Mr. VanOort previously held the position of Executive Chairman and Interim Chief Executive Officer of the Company from March 16, 2009 until October 28, 2009. Mr. VanOort also serves as the Chairman of the Company's Board of Directors. Since 2004, Mr. VanOort has served as a General Partner and an Operating Partner of Summer Street Capital Partners, LLC, a private equity firm. Since 2000, Mr. VanOort has also served as a Founding Partner and General Partner of Conundrum Capital Partners, LLC, a management advisory and investment firm. In addition, since 2000, Mr. VanOort has served as the Chairman, Co-Founder and Co-Owner of Vision Ace Hardware, LLC, a retail hardware chain. Mr. VanOort is a graduate of Bentley College. On October 28, 2009, the Company entered into an Amended and Restated Employment Agreement with Mr. VanOort (the "Employment Agreement") to employ Mr. VanOort in the capacity of Chief Executive Officer. The Employment Agreement provides for an initial employment term from March 16, 2009 through March 16, 2013, which initial term automatically renews for one year periods. Mr. VanOort will receive a salary of $325,000 per year. Mr. VanOort is also eligible to receive an annual cash bonus based on the achievement of certain performance metrics pursuant to the Company's Management Incentive Plan. Mr. VanOort's target bonus under such plan is 60% of his base salary (the "Target Bonus"), however, Mr. VanOort could be eligible to receive up to 150% of the Target Bonus in the event that the Company's and/or Mr. VanOort's performance exceeds the thresholds set for the Target Bonus. Mr. VanOort is also entitled to pa...
Click here to read the whole Article (external link)

Q3 2009 NEOGENOMICS INC Earnings Release - Time Not Supplied

Earnings Announcements for Thursday, October 29CompanySymbolTimeConferenceCall3PAR Inc.PARAfter Market CloseListenABBABB01:00 am ETABG SUN COL HLDGASC.OLTime Not SuppliedAccuray IncorporatedARAYAfter Market CloseListenACHENG RELAY000922.SZTime Not SuppliedAcme Packet, Inc.APKTAfter Market CloseListenAcme UnitedACU09:00 am ETListenACS, Actividades de Construcción y Servicios, S.A.ACS.MCAfter Market CloseACTELIOSACT.MI10:00 am ETActuate CorporationACTUAfter Market CloseListenAdaptec, Inc.ADPTTime Not SuppliedListenAdolor CorporationADLRTime Not SuppliedListenADVA Optical NetworkingADV.FTime Not SuppliedListenAetna Inc.AETBefore Market OpenListenAGL ResourcesAGLBefore Market OpenListenAgree Realty...
Click here to read the whole Article (external link)

NeoGenomics Reports Third Quarter 2009 Results

FT. MYERS, Fla., Oct. 29 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2009. Highlights:Revenue increased by $2.2 million or 44% to $7.3 million in the third quarter from $5.1 million in the same quarter last year. The number of tests increased by 33% while average revenue per test increased by 8%. Gross profit margin of 50% was essentially unchanged from last year. Sales and marketing expenses increased $989,000 or 123% driven by a more than doubling in the size of the sales force since this time last year. General and administrative expenses increased $626,000 or 34% primarily due to an increase in management personnel. Net loss for the quarter was ($755,000) or ($0.02)/share versus a net loss of ($195,000) or $0.01/share in Q3 08.During the third quarter, NeoGenomics received $4.8 million of proceeds from the sale of 3.5 million shares of common stock to Abbott Laboratories and received an additional $640,000 upon the exercise of certain warrants. As a result of these equity transactions, all non-lease debt was paid off during the quarter. At the end of the Quarter, the Company held $3.1 million of cash and retained $3 million of availability on its working capital credit facility.During the third quarter, overall revenue growth was impacted by normal seasonality in Florida-based accounts as well as by a restructuring of the relationship with the company's largest account. As previously disclosed, we recently began assisting our largest customer develop the capability to perform bladder cancer FISH testing in-house while seeking to expand the scope of other testing services and the number of locations for which we provide services. As a result,...
Click here to read the whole Article (external link)

NeoGenomics Schedules Its Q3 2009 Earnings Release for October 29, 2009

FT. MYERS, Fla., Oct. 27 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today that it plans to release its third quarter 2009 financial results on Thursday, October 29, 2009. http://www.neogenomics.org or http://www.investorcalendar.com/IC/CEPage.asp?ID=151457. An archive of the web-cast will be available until 11:59 PM EDT on October 29, 2010.About NeoGenomics, Inc.NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit ...
Click here to read the whole Article (external link)

NeoGenomics to Present at the Rodman & Renshaw Healthcare Investment Conference on September 10, 2009

FT. MYERS, Fla., Sept. 3 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM - News) announced today that it will present at the Rodman & Renshaw 11th Annual Healthcare Conference being held from September 9-11, 2009 at the New York Palace Hotel in New York City. The conference will showcase small and microcap public life sciences and biotech companies. Senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference. NeoGenomics is scheduled to present on Thursday, September 10th at 3:40 PM EDT in the Fahnestock Salon on the fifth floor of the hotel. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq15/ngnm.ob. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months.Abou...
Click here to read the whole Article (external link)

NEOGENOMICS INC Financials

PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue7,459  6,914  5,920  5,051  Cost of Revenue3,384  3,090  2,776  2,535  Gross Profit4,075  3,823  3,144  2,515  Operating ExpensesResearch Development -   -   -   -  Selling General and Administrative3,937  3,675  3,839  2,636  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss139  148  (695)(120)Income from Continuing OperationsTotal Other Income/Expenses Net -   -  (190) -  Earnings Before Interest And Taxes139  148  (885)(120)Interest Expense130  115  109  75  Income Before Tax8  33  (994)(195)Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops8  33  (994)(195)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes - &n...
Click here to read the whole Article (external link)

AMI Research Publishes Q2 2009 Stock Report on NeoGenomics

KEY LARGO, FL--(Marketwire - 08/11/09) - AMI Research, a division of Hawk Associates, today announced that it has updated its stock opinion of NeoGenomics, Inc. (OTC.BB:NGNM - News) based on the company's second quarter results. The 20-page stock research report on NeoGenomics is comprehensive and informative. It's a look into the company's core business model, financial history and future prospects. AMI's report details the impact of NeoGenomics' strategic supply agreement with the healthcare giant Abbott Health. The report projects a favorable outcome regarding the company's initiative to develop a FISH-based skin cancer test and AMI also reports that NeoGenomics has recently restructured one of its alliances to enlarge its product portfolio and widen its geographical footprint.To read AMI Research's report on NeoGenomics' recent news, key statistics, healthcare industry trends and more the stock report is available to download for free at: http://www.amistockreports.com.NeoGenomics specializes in cancer genetics, flow cytometry and molecular diagnostic testing. The company's laboratories offer superior service, industry leading turnaround times and complete dedication to its clients and patients. Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, CA and Fort Myers and provi...
Click here to read the whole Article (external link)

NEOGENOMICS INC Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS NeoGenomics, Inc., a Nevada corporation (referred to individually as the "Parent Company" or collectively with all of its subsidiaries as "NeoGenomics" or the "Company" in this Form 10-Q) is the registrant for SEC reporting purposes. Our common stock is listed on the OTC Bulletin Board under the symbol "NGNM." Introduction The following discussion and analysis should be read in conjunction with the unaudited consolidated condensed financial statements, and the notes thereto included herein. The information contained below includes statements of the Company's or management's beliefs, expectations, hopes, goals and plans that, if not historical, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this Quarterly Report on Form 10-Q under the caption "Forward Looking Statements", which information is incorporated herein by reference. Critical Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. While many operational aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward with net revenues primarily recognized upon completion of the testi...
Click here to read the whole Article (external link)

NEOGENOMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal O

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 21, 2009, the Board of Directors of the Company appointed Grant Carlson, age 50, to the position of Vice President of Sales and Marketing. Mr. Carlson had previously served as a consultant to the Company since December 2008. Mr. Carlson served as the President and Chief Executive Officer of Calgenex Corporation, a nutraceutical company which he co-founded, from March 2006 to June 2008. From April 2004 to February 2006, Mr. Carlson served as President and Chief Operating Officer of Nanobac Pharmaceuticals Incorporated, a pharmaceutical and diagnostic company. Mr. Carlson served as Vice President, Marketing and Business Development of Agilix Corporation, a functional genomics company, from April 2001 to April 2004. From January 1989 to April 2001, Mr. Carlson was employed by Dianon Systems, Inc., an anatomic pathology laboratory, lastly in the position of Vice President, Marketing & Business Development. Mr. Carlson received a B.S. degree in Kinesiology from the University of California, Los Angeles. The Company and Mr. Carlson are parties to an offer letter dated July 22, 2009 (the "Offer Letter"). The Offer Letter provides for a four (4) year term, which is terminable upon written notice by either party. The Offer Letter also provides for an initial base salary of $200,000 per year and provides that Mr. Carlson is eligible to receive an incentive bonus targeted at 30% of his base salary based on the achievement of certain goals. Mr. Carlson is entitled to participate in all medical and other benefits that the Company has established for its employees. Mr. Carlson also is entitled to an automobile allowance of $700 per month (plus reimbursement for work-related gas expenses) and reimbursement for personal telephone and cell phone use at a rate of $250 per month. Mr. Carlson is also eligible for four (4)...
Click here to read the whole Article (external link)